Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma

Kuniki Kawaguchi(Japanese Foundation For Cancer Research), Shunji Takahashi(Japanese Foundation For Cancer Research), Naoki Fukuda(The Cancer Institute Hospital), Makiko Ono(The Cancer Institute Hospital), Kenji Nakano(National Center for Global Health and Medicine), Seiichi Matsumoto(Fukuda Denshi (Japan)), Keisuke Ae(The Cancer Institute Hospital), Masatoshi Nishizawa(Japanese Foundation For Cancer Research), Tetsuya Urasaki(Japanese Foundation For Cancer Research), Shinichiro Taira(Japanese Foundation For Cancer Research), Junichi Tomomatsu(The Cancer Institute Hospital)
In Vivo
January 1, 2019
10.21873/invivo.11644
Cited by 7

Related Papers

Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264
Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases
|International Journal of Radiation Oncology*Biology*Physics|2016|182
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus
|Molecular Therapy|2012|117